CD47

Cluster of Differentiation 47; MER6; OA3

CD47 is a glycoprotein that was first identified in 1990 as a protein that associates with integrins, hence its original name integrin-associated protein. CD47 interacts with SIRPα (CD172a or SHPS-1) and its family member SIRPγ, CD47 also interacts with integrins and secreted glycoprotein extracellular matrix protein thrombospondin-1 (TSP-1). Signaling through the CD47/SIRPα axis plays a role in various homeostatic processes, such as maintenance of erythrocytes, innate immune cells and T cells. Moreover, cancer cells and virus-infected and bacteria-infected cells can upregulate CD47 protein expression to prevent immune-mediated elimination.

CD47 Inhibitors (34)

CD47 Related Products (43):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P990694

Zeripatamig	Inhibitor	≥99.0%
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990555

BI-765063	Inhibitor
BI-765063 is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4PE type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.36 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P99950

Evorpacept	Inhibitor	99.75%
Evorpacept is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region.

HY-115983

DMUP	Inhibitor	≥98.0%
DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity.

HY-151132

Glutaminyl cyclases-IN-1	Inhibitor	98.21%
Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC₅₀ values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages.

HY-143224

NCGC00138783	Inhibitor
NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis.

HY-P990899

Amostomig
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096).

HY-P991004

Itanistomig
HY-P991004 is an CD274/CD47-targeting (VH-G1CH1-h)-H-γ1_L-κ-L-κ type bispecific antibody.

HY-P990954

Amulirafusp alfa
HY-P990954 is an MS4A1/CD47-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991016

Peluntamig
HY-P991016 is an CD47/DLL3-targeting H-γ1_L-κ type bispecific antibody.

HY-P3968

Thrombospondin-1 (1016-1021) (human, bovine, mouse)
Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity.

HY-P10813

ZLIRTLHEWY	Inhibitor
ZLIRTLHEWY is a potent peptide CD47/SIRPα interaction inhibitor. ZLIRTLHEWY is promising for research of cancers.

HY-143224A

NCGC00138783 free base	Inhibitor
NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis.

HY-143225

NCGC00538431	Inhibitor
NCGC00538431 is a potent modulator of SIRPα-CD47.

HY-P990707

Maplirpacept
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47.

HY-P991366

IBI-397	Inhibitor
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research.

HY-RS02250

CD47 Human Pre-designed siRNA Set A	Inhibitor
CD47 Human Pre-designed siRNA Set A contains three designed siRNAs for CD47 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CD47 Human Pre-designed siRNA Set A CD47 Human Pre-designed siRNA Set A

HY-P991561

AO-176	Inhibitor
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma.

HY-P991057

STI-6643	Inhibitor
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P991027

Spevatamig
HY-P991027 is an CD47/CLDN18-targeting (H-γ1_L-κ)_(H-γ1_L-κ) type bispecific antibody.

Name
Email *

	Sorry, but the email address you supplied was invalid.